Drug Trial Radar · NCT06052813
A Study of BN104 in the Treatment of Acute Leukemia
Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
66
Actual
Start
Oct 19, 2023
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.
Conditions
- ALL, Adult
- AML, Adult
- Acute Leukaemia
- KMT2A Rearrangement
- NPM1 Mutation
- NUP98 Gene Rearrangement
- Menin Inhibitors
Interventions
BN104 monotherapyDrug
Phase I(adults): Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
BN104 monotherapyDrug
Phase I(adolescent): Will be administered orally twice daily (approximately every 12 hours)
BN104 monotherapy - rp2dDrug
receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)
Primary outcomes
What the sponsor says the trial is designed to measure.
- PhaseI Incidence of Dose Dose limiting toxicities(DLTs)Time frame: DLT last 28days(at the end of cycle 1 for each dose)
- PhaseI Incidence of serious adverse events(SAEs)Time frame: 36 month
- PhaseII efficacy assessmentTime frame: 36 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.